Home LiteratureArticle Details
PMID: 15385655 Published · ppublish English Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.

The New England journal of medicine ·Vol. 351 ·No. 13 ·2004-09-23 ·Pages 1285-95

Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA

Abstract

The presence of coexisting conditions has a substantial effect on the outcome of acute myocardial infarction. Renal failure is associated with one of the highest risks, but the influence of milder degrees of renal impairment is less well defined. As part of the Valsartan in Acute Myocardial Infarction Trial (VALIANT), we identified 14,527 patients with acute myocardial infarction complicated by clinical or radiologic signs of heart failure, left ventricular dysfunction, or both, and a documented serum creatinine measurement. Patients were randomly assigned to receive captopril, valsartan, or both. The glomerular filtration rate (GFR) was estimated by means of the four-component Modification of Diet in Renal Disease equation, and the patients were grouped according to their estimated GFR. We used a 70-candidate variable model to adjust and compare overall mortality and composite cardiovascular events among four GFR groups. The distribution of estimated GFR was wide and normally shaped, with a mean (+/-SD) value of 70+/-21 ml per minute per 1.73 m2 of body-surface area. The prevalence of coexisting risk factors, prior cardiovascular disease, and a Killip class of more than I was greatest among patients with a reduced estimated GFR (less than 45.0 ml per minute per 1.73 m2), and the use of aspirin, beta-blockers, statins, or coronary-revascularization procedures was lowest in this group. The risk of death or the composite end point of death from cardiovascular causes, reinfarction, congestive heart failure, stroke, or resuscitation after cardiac arrest increased with declining estimated GFRs. Although the rate of renal events increased with declining estimated GFRs, the adverse outcomes were predominantly cardiovascular. Below 81.0 ml per minute per 1.73 m2, each reduction of the estimated GFR by 10 units was associated with a hazard ratio for death and nonfatal cardiovascular outcomes of 1.10 (95 percent confidence interval, 1.08 to 1.12), which was independent of the treatment assignment. Even mild renal disease, as assessed by the estimated GFR, should be considered a major risk factor for cardiovascular complications after a myocardial infarction.

MeSH Terms
Aged Angiotensin II Type 1 Receptor Blockers Angiotensin-Converting Enzyme Inhibitors/therapeutic use Captopril/therapeutic use Cardiovascular Diseases/etiology,mortality Chronic Disease Creatinine/blood Double-Blind Method Drug Therapy, Combination Female Glomerular Filtration Rate Humans Kidney Diseases/complications,diagnosis Male Middle Aged Myocardial Infarction/blood,complications,drug therapy,mortality Proportional Hazards Models Risk Factors Survival Rate Tetrazoles/therapeutic use Valine/analogs & derivatives,therapeutic use Valsartan
Chemicals
Angiotensin II Type 1 Receptor Blockers Angiotensin-Converting Enzyme Inhibitors Tetrazoles Valsartan Captopril Creatinine Valine
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Anavekar Nagesh S
Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA.
McMurray John J V
Velazquez Eric J
Solomon Scott D
Kober Lars
Rouleau Jean-Lucien
White Harvey D
Nordlander Rolf
Maggioni Aldo
Dickstein Kenneth
Zelenkofske Steven
Leimberger Jeffrey D
Califf Robert M
Pfeffer Marc A
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
Published
2004-09-23
Pages
1285-95
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com